Fresenius completes mAbxience deal and Fresenius stock sits 19.43 percent below its high

Published on 10/12/2026 at 10:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 42.67 on October 12, 2026 versus the EUR 42.35 Xetra close.

Key points in brief

Fresenius completed its acquisition of the remaining 45 percent of mAbxience for up to EUR 750.0 million on October 1, 2026.
Q2 2026 revenue rose 6.00 percent year over year to EUR 5.864 billion, while core net income increased 14.00 percent.
Fresenius stock was trading at EUR 42.67 at Lang & Schwarz on October 12, 2026, 0.76 percent above the Xetra close of October 9, 2026.
Jefferies maintained a Buy rating and a EUR 55.00 price target on October 2, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 42.67 at Lang & Schwarz on October 12, 2026 at 10:30 a.m. CEST, 0.76 percent above the Xetra close of October 9, 2026 at EUR 42.35 and 19.43 percent below its 52-week high of EUR 52.96. Fresenius completed the acquisition of the remaining 45 percent of mAbxience for up to EUR 750.0 million on October 1, 2026, according to Fresenius.

Full ownership targets biosimilars growth

The transaction gives Fresenius Kabi full ownership of the biosimilars platform and includes a contingent payment of EUR 50.0 million tied to production-site approvals. The deal was signed and completed on September 30, 2026, with no regulatory approvals required, according to EQS News.

mAbxience generated more than EUR 320.0 million in revenue in fiscal year 2025, while its portfolio comprised four marketed products and eight development candidates. Fresenius said the acquisition should contribute immediately to adjusted earnings per share, while 2026 guidance remained unchanged.

Q2 results show higher earnings quality

In the second quarter of 2026, group revenue increased 6.00 percent year over year to EUR 5.864 billion, according to Fresenius. Group EBIT rose 10.00 percent to EUR 719.0 million, while core net income increased 14.00 percent to EUR 470.0 million and core earnings per share reached EUR 0.83.

The latest figures give the mAbxience purchase a measurable operating backdrop: Fresenius entered the deal after a quarter in which revenue and core net income both expanded at least 6.00 percent. That comparison matters because the company expects the fully owned platform to add to adjusted earnings per share immediately rather than only after a long integration period.

What does the deal mean for valuation?

Jefferies maintained a Buy rating and a EUR 55.00 price target on October 2, 2026, according to wallstreetONLINE. The target stands 28.63 percent above the Lang & Schwarz price of EUR 42.67, using both values in euros. The report highlighted biosimilars, medical technology and nutrition as areas to discuss with Chief Executive Michael Sen.

Three milestones frame the next step

On September 7, 2026, Fresenius sold 7.8 million Fresenius Medical Care shares for EUR 300.0 million; on September 16, 2026, it said 1,700 employees would move into Helios from January 1, 2027; and on October 1, 2026, it completed the mAbxience transaction for up to EUR 750.0 million, according to Fresenius.

Next reporting date is November 4

Fresenius lists November 4, 2026 as the next event, with a conference call for third-quarter 2026 results, according to Fresenius. The date gives investors the next scheduled checkpoint for testing whether the raised full-year outlook remains supported by operating performance.

Stock remains below its yearly high

Fresenius stock had a market capitalization of EUR 24.0 billion as of October 12, 2026, while its 52-week range was EUR 35.11 to EUR 52.96. The current EUR 42.67 price therefore sits closer to the midpoint of that range than to the yearly high, even as the mAbxience transaction adds full ownership to the growth portfolio.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.